CORDIS
EU research results

CORDIS

English EN
Translational Kinase Tumour Inhibitor discovery Consortium

Translational Kinase Tumour Inhibitor discovery Consortium

Objective

Protein kinases are involved in the control of a large number of cellular processes and play a central role in human physiology. More than 500 genes encoding protein kinases have been identified in the human genome, and it is estimated that about 30% of all human proteins may be phosphorylated by kinases. Deficiency in kinase activity has implications in cancer, central nervous system disorders, autoimmune diseases and immunosuppression, diabetes, osteoporosis and various metabolic disorders. Small-molecule kinase inhibitors have therefore moved into the focus of the pharmaceutical industry as a new class of drugs, which is expected to produce new and more efficient treatments and grow significantly within the coming decade.

The proposed project brings together the unique and proprietary technologies of three SMEs and the expertise of academic research partners to create a new platform for lead compound discovery with a focus on protein kinases. Three kinases will be targeted for the development of inhibitory compounds. The academic partners will contribute a modern high throughput platform for protein expression and crystallisation (Israel Structural Proteomics Centre), and expertise in the biochemistry and biology of the targeted kinases combined with the principles of the use of bioisosterism in synthesis of novel chemical compounds (University of Turin). The applied principles and technologies will provide new IP opportunities for the partner SMEs in the otherwise crowded kinase inhibitor IP space and will help in the design of new strategies in the discovery of inhibitors for novel kinase targets in the treatment of cancer. The generated compounds will be sold and/or out-licensed to large pharmaceutical companies for continued development. This market is currently undergoing continuous expansion due to large cuts in early drug discovery within most pharmaceutical companies.

Coordinator

SAROMICS BIOSTRUCTURES AB

Address

Medicon Village
223 81 Lund

Sweden

Activity type

Other

EU Contribution

€ 407 700

Administrative Contact

Salam Al-Karadaghi (Prof.)

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

PRESTWICK CHEMICAL SAS

France

EU Contribution

€ 382 831

KTB TUMORFORSCHUNGSGESELLSCHAFT MBH

Germany

EU Contribution

€ 358 466

UNIVERSITA DEGLI STUDI DI TORINO

Italy

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

WEIZMANN INSTITUTE OF SCIENCE LTD

Israel

Project information

Grant agreement ID: 315746

Status

Closed project

  • Start date

    1 February 2013

  • End date

    31 March 2015

Funded under:

FP7-SME

  • Overall budget:

    € 1 477 337

  • EU contribution

    € 1 148 997

Coordinated by:

SAROMICS BIOSTRUCTURES AB

Sweden